STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies* 

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the	1
		title or the abstract	
		(b) Provide in the abstract an informative and balanced summary of	1-2
		what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the	3
		investigation being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	4-7
Setting	5	Describe the setting, locations, and relevant dates, including	4-6
		periods of recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of	4-6
	-	selection of participants	
Variables	7	Clearly define all outcomes, exposures, predictors, potential	6
		confounders, and effect modifiers. Give diagnostic criteria, if	
		applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of	4-6
measurement		methods of assessment (measurement). Describe comparability of	
		assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	4-6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If	6-7
Quantitutive variables	- 11	applicable, describe which groupings were chosen and why	0 /
Statistical methods	12	(a) Describe all statistical methods, including those used to control	6-7
		for confounding	
		(b) Describe any methods used to examine subgroups and	6-7
		interactions	,
		(c) Explain how missing data were addressed	
		(d) If applicable, describe analytical methods taking account of	6-7
		sampling strategy	
		(e) Describe any sensitivity analyses	
Doculto		<u></u>	<u> </u>
Results Participants	13*	(a) Report numbers of individuals at each stage of study—eg	7
1 articipants	13	numbers potentially eligible, examined for eligibility, confirmed	,
		eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Denovinal 1	1.4 *		
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic,	
		clinical, social) and information on exposures and potential	
		confounders  (b) In direct receives a fraction of the principle data for each	
		(b) Indicate number of participants with missing data for each	
0	154	variable of interest	7.10
Outcome data	15*	Report numbers of outcome events or summary measures	7-10

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and	7-10, Figures
		why they were included	
		(b) Report category boundaries when continuous variables were	Figures
		categorized	stratified by
			age
		(c) If relevant, consider translating estimates of relative risk into	
		absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and	7-10,
		interactions, and sensitivity analyses	Figures
Discussion			
Key results	18	Summarise key results with reference to study objectives	10-11
Limitations	19	Discuss limitations of the study, taking into account sources of	11-12
		potential bias or imprecision. Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering	10-11
		objectives, limitations, multiplicity of analyses, results from similar	
		studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
Other information			
Funding	22	Give the source of funding and the role of the funders for the	12
		present study and, if applicable, for the original study on which the	
		present article is based	

<sup>\*</sup>Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.